

Adherium Hailie Smartinhaler Quarter-to-Date Sales Update

Highlights:

- Positive commercial momentum behind the Hailie® Smartinhaler® and cloud-based platform has continued since Adherium's last sales update, released to ASX on 16 December 2025.
- The Company has demonstrated a 51% increase in Remote Patient Monitoring (RPM) revenue from \$68k in December 2025 to A\$103k in February 2026.
- RPM revenue in January and February 2026 of A\$198k has already surpassed Q2 FY26 total RPM revenue of A\$171k with one month remaining.
- Performance underpinned by the Company's investment in the Adherium Care Team and its infrastructure to facilitate the growth in RPM device shipments and activations.
 - Notably, the newly established CPT reimbursement codes (effective 1 January 2026) have lowered required thresholds to bill patients, enabling earlier billing and improved billing efficiency, marking a significant tailwind for CY2026.
- Total (cumulative) RPM device shipments increased from 2,149 at 31 December 2025 to 3,071 as at 28 February 2026, representing a 43% increase in the first two months of CY2026.
- Total (cumulative) RPM device activations increased by 53% in the first two months of CY2026, from 1,425 as at 31 December 2025, to 2,183 as at 28 February 2026.
 - Following strong RPM device shipments in the December month, the Adherium Care Team was able to successfully drive conversions of shipped RPM devices into activated RPM patients. Highlighting the effectiveness of Adherium's RPM commercial model.
- The Company is encouraged by these results and the continued trajectory of its expanding RPM commercial model.
 - Through Adherium's Call Centre and via partners (including Allergy Partners), Adherium now has access to approximately 48,000 valid insurance-verified asthma patients with compatible inhaler devices, highlighting the increasing pipeline and scalability of the RPM model.

Melbourne, Australia – 10 March 2026: [Adherium Limited](#) (ASX:ADR), a global leader in digital respiratory management and developer of the FDA-cleared Hailie® Smartinhaler® platform, is pleased to provide a sales update, following recent significant progress with its commercial strategy.

Adherium's CEO, Dawn Bitz, commented: *"In a short space of time, we've scaled sales under our Remote Patient Monitoring model from zero at the start of 2025 to A\$103k per month as at end February 2026."*

Through our collaboration with Allergy Partners, we've built a major platform for growth - clinicians want patients to have our technology and patients are benefitting significantly from improved respiratory outcomes.

With the benefit of these initiatives and reimbursement tailwinds, we have strong confidence in delivering our previously announced target of 10,000 RPM patients by the end of 2026."

New CPT Reimbursement Codes:

On 1 January 2026, US CPT codes 99445 and 99470 were added by the American Medical Association and Finalised my CMS.

- CPT 99445 lowers the minimum data requirement to bill a patient to two days of data, per month. The existing CPT code 99454 required at least 16 days of data, per month to bill a patient and both codes have identical economics.
 - This materially reduces the billing threshold, increasing the speed at which patients become billable and billing efficiency.
- CPT 99470 enables Adherium to bill for monthly consultations of between 10-to-19 minutes at ~US\$26 per patient, per month.
 - If the consultation exceeds 19 minutes, CPT 99457 is billed instead at the usual economics of ~US\$52 per patient per month.

The new CPT codes provide a further strong tailwind for commercial growth in CY2026 as the Adherium Call Centre continues to onboard patients to the Hailie Platform.

Outlook:

Adherium continues to drive commercialisation of its RPM recurring model with an established infrastructure and call centre now generating strong results in identifying and activating patients onto the Hailie Platform. The Company maintains its target of 10,000 RPM patients by CY2026 end, and today's sales update reaffirms the Company's confidence in achieving this milestone.

Adherium looks forward to having the Intermountain Health iCARE Study clinical, economic and patient impact data officially released and presented at the American Thoracic Society International Conference between 15-20 May 2026. This data is expected to further validate the Hailie Platform by highlighting the positive health outcomes generated through increased medication adherence in asthma and COPD, which are some of the most economically burdensome health conditions in the United States. The Company will seek to use this data upon final release to continue engagement with U.S. payers/insurers in relation to value-based care contracts.



ASX Release

Learn more at adherium.com

This ASX announcement was approved and authorised for release by the Board of Adherium.

- ENDS -

Investor Enquiries

Adherium Limited

investors@adherium.com

Media Enquiries:

Haley Chartres

HACK Director

haley@hck.digital

About Adherium (ASX: ADR):

Adherium is a provider of integrated digital health solutions and a worldwide leader in connected respiratory medical devices, with more than 180,000 sold globally. Adherium's Hailie® platform solution provides clinicians, healthcare providers and patients access to remotely monitor medication usage parameters and adherence, supporting reimbursement for qualifying patient management. The Hailie® solution includes a suite of integration tools to enable the capture and sharing of health data via mobile and desktop apps, Software Development Kit (SDK) and Application Programming Interface (API) integration tools, and Adherium's own broad range of sensors connected to respiratory medications. Adherium's Hailie® solution is designed to provide visibility to healthcare providers of medication use history to better understand patterns in patient respiratory disease. Learn more at [**adherium.com**](https://adherium.com)